2 studies found for:    NCT00390221
Show Display Options
RSS Create an RSS feed from your search for:
NCT00390221
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Subjects With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: Daclizumab High Yield Process 150 mg;   Biological: Daclizumab High Yield Process 300 mg
2 Completed Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BIIB019 (Daclizumab High Yield Process);   Drug: Placebo

Indicates status has not been verified in more than two years